Ifosfamide in the treatment of malignant epithelial ovarian tumors.
Ifosfamide is one of the best-known alkylating agents. In advanced epithelial ovarian cancer, it has been tested in association with cisplatin, achieving results equal, if not better than cyclophosphamide, with acceptable toxicity. In second-line therapy, it shows remarkable activity, even in patients refractory to cisplatin already treated with cyclophosphamide, with more severe, but always manageable toxicity. In gynecological sarcomas, ifosfamide is, together with doxorubicin, the reference drug for chemotherapy.
Clinica Ostetrica e Ginecologica, Università degli Studi Milano-Bicocca, Ospedale S. Gerardo dei Tintori, Monza, Italy. alissoni@iol.it
A A
AA
Lissoni
F
F
Fei
R
R
Rossi
R
R
Fruscio
A
A
Villa
G
G
Zani
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide